Proteasome inhibition and its therapeutic potential in multiple myeloma
Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA; 2New York University School of Medicine, New York, NY, USAAbstract: Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA...
Enregistré dans:
Auteurs principaux: | Ajai Chari, Amitabha Mazumder, Sundar Jagannath |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2010
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/bfa5dae794bc4d58b562ef9039d50e04 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
par: Feng Ge, et autres
Publié: (2010) -
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma
par: Hector H. Huang, et autres
Publié: (2020) -
Profile of elotuzumab and its potential in the treatment of multiple myeloma
par: Liu YC, et autres
Publié: (2014) -
Front line treatment of elderly multiple myeloma in the era of novel agents
par: Marie-Dominique Venon, et autres
Publié: (2008) -
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
par: Nooka A, et autres
Publié: (2013)